Risk Stratification in CAD and PAD

Slides:

Advertisements

Similar presentations

HCS Objective To determine if measurement of postprandial TG level improves risk prediction of CV events over traditional risk markers in stable patients.

Advertisements

Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.

Andre Lamy on behalf of the COMPASS Investigators

Monitoring and Modifying Treatment in PAH

Preventing Thrombotic Complications in ACS: State of the Art

Updates in Anticoagulation: What Did We Learn From ESC 2017?

US Guidelines US Guidelines Low-risk Patients.

Achieving Long-Term Protection Post-MI

Preventing SCD With a WCD: Reviewing the Results of the VEST Trial

When Is Adding Aspirin to NOACs Worth the Risk?

Heart Rate, HF Admissions, and Readmissions

The ABCs of AF.

NOACs in Clinical Practice: Are They All the Same?

New Strategies to Prevent CV Events After Hospital Discharge

PAD Patients vs Post-ACS Patients:

A New Era for NOACs:.

Patient 1: 53-Year-Old Man With CVD Risk Factors

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Select Topics in Cardiovascular Medicine

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Case Study: 45-year-old Man

Antithrombotics and PAD: A New Paradigm in Practice

New Perspectives in CAD and PAD: Weighing the Latest Evidence

What Has Been Tried and What Is True?

Oral Anticoagulants in AFa,b A Brief History.

Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.

Surveying the Safety of NOACs in the Real World

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Antiplatelet Therapy and Secondary Prevention

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

Are We Closer to Personalized Medicine in MS?

Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

CV Risk Doesn't End in the Cath Lab

AF and PCI in Practice.

Antithrombotic Protection in CAD and HF

TAVR and the Risk of Thrombosis

Understanding PAD.

Oral Anticoagulation in AF

Practical Strategies to Reduce HF Hospitalizations in African American Patients.

Extending Treatment for Thrombosis: What’s the Right Choice?

Aspirin in Cardioprevention:

Type 2 Diabetes Management: Where Are We Heading in Our Efforts to Control CV Risk?

Personalized Therapy in Relapsed or Refractory CLL

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

CV Risk Doesn't End in the Cath Lab

Anticoagulation and Thrombosis Management

Updates in Heart Failure:

Aspirin and Cardioprevention in 2018

Identifying High-Risk AF Patients

Factor Xa Inhibitors in PAD

CAD/PAD in Primary Care

CAD and HF Often Coexist

Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.

Antithrombotic Therapy in PAD

Antithrombotic Therapy in Vascular Protection: From CAD to HF

Updates in Anticoagulation: Key Sessions at ESC 2017

Program Goals Background: Anticoagulation in Patients With VTE.

Reducing Risk for CV Outcomes

Factor Xa Inhibitors in Coronary Artery Disease

The ABCs of AF.

5 Good Minutes on Atrial Fibrillation-related Stroke

Reassessing Risk Stratification in CAD/PAD

My PAH Patient.

PCSK9 Inhibitors and Real-World Evidence

Case-Based Look at Hyperkalemia Identification, Diagnosis, and Management.

What's New in NOACs in AF?.

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Translating Data From Trial to Practice

Presentation transcript:

Risk Stratification in CAD and PAD

COMPASS Trial Design

COMPASS Efficacy Outcomes

COMPASS PAD MALE and Major Amputation

COMPASS Bleeding Outcomes

COMPASS HF Net Clinical Benefit

COMPASS HF Major Bleeding

COMMANDER HF Design

Case #1: 64-Year-Old Woman

Case #1: 64-Year-Old Woman (cont) December 2017 Follow-Up

COMPASS Entry Criteria

Case #1: 64-Year-Old Woman (cont) July 2018 Follow-Up

Case #1: Meets Compass Entry Criteria

Rivaroxaban New European Indication

Case #2: 78-Year-Old Man

Case #2: 78-Year-Old Man CVD Prevention Strategies

ASCEND Aspirin for Primary Prevention in DM

Case #2: 78-Year-Old Man (cont) May 2018 Follow-Up

Case #2: 78-Year-Old Man (cont) Coronary Angiography

Case #2: Meets Compass Entry Criteria

COMMANDER HF: Patients With Recent Worsening of CHF, Reduced EF, and CAD and With No AF

Summary

Abbreviations

Abbreviations (cont)